Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis

Rennie, George E.; Wilkinson, Angus J.; White, Andrew; Ruospo, Marinella; Teixeira‐Pinto, Armando; Strippoli, Giovanni F.M.

doi:10.1080/03007995.2019.1595553

Cited by 5 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…targeting ECM accumulation in the TM. Moreover, the currently available anti-glaucoma agents can only decrease IOP, but not prevent the progression of, nor cure POAG ( 20 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

et al. 2022

View full text Add to dashboard Cite

To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo , and to investigate its related molecular pathway in vitro , an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)-β2 in the right eye of BALB/cJ mice, while the left was treated with an empty control adenovirus. To determine its anti-intraocular hypertension role, these induced hyper-IOP mice were gavaged with atorvastatin (20 mg/kg/day). Furthermore, extracellular matrix (ECM) factors were examined in the primary human trabecular meshwork (HTM) cells followed atorvastatin (0~200 µ M) treatment in vitro . Whole genome microarray was employed to identify potential therapeutic target molecules associated with ECM regulation. Unilateral murine ocular hypertension was induced, via intravitreal injection of the adenoviral vector carrying the human TGF-β2 gene (Ad.hTGF-β2 226/228 ), raising IOP from 12±1.6 to 32.3±0.7 mmHg (n=6, P<0.05) at day 15, which plateaued from day 15 to 30. Atorvastatin administration from day 15 to 30 decreased IOP from 32.3±0.7 to 15.4±1.1 mmHg (n=6, P<0.05) at day 30. Additionally, atorvastatin administration changed the morphology of cultured HTM cells from an elongated and adherent morphology into rounded, less elongated and less adherent cells, accompanied with suppressed expression of ECM. Gene Ontology and Genome analysis revealed that FGD4 (FYVE, RhoGEF and PH domain containing 4) might be a key factor contributing to these changes. Our data demonstrated that atorvastatin reduced TGF-β2-induced ocular hypertension in vivo , perhaps via modifying cellular structure and decreasing ECM, using the FGD4 signaling pathway, as demonstrated in HTM cells. Our findings provide some useful information for the management of glaucoma, with statin therapy revealing a potential novel therapeutic pathway for glaucoma treatment.

show abstract

“…targeting ECM accumulation in the TM. Moreover, the currently available anti-glaucoma agents can only decrease IOP, but not prevent the progression of, nor cure POAG ( 20 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

et al. 2022

View full text Add to dashboard Cite

show abstract

The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers

Kolli

Toris

Reed

et al. 2021

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Management of the glaucoma patient progressing at low normal intraocular pressure

Wang

Singh

2020

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review Patients with glaucoma with disease progression despite low or normal intraocular pressure (IOP) present special challenges to the treating clinician. Treatment goals may depend on whether patients have apparent low IOP with concurrent treatment or have low IOP at baseline without treatment. We review the diagnostic and therapeutic approaches to these patients. Recent findings Apparent progression at low IOP should start with confirmation of IOP, made easier by devices enabling patient home self-tonometry. Suspected visual field progression should be confirmed by repeat testing prior to advancement of therapy. Trabeculectomy remains the most effective surgical method of achieving long-term success, particularly when there is a low starting IOP. Drainage tube implantation or the use of novel micro-incisional non-bleb-forming procedures are less likely to be successful in achieving low IOP goals. Summary Diagnostic testing is important in confirming progressive glaucomatous disease at low IOP levels. The most effective way of slowing the progression of glaucoma in a patient with low IOP is to lower the IOP further, sometimes to single digit levels, which is most often achievable with trabeculectomy.

show abstract

Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis

Cited by 5 publications

References 57 publications

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers

Management of the glaucoma patient progressing at low normal intraocular pressure

Contact Info

Product

Resources

About